{"id":"arimidex-dummy","safety":{"commonSideEffects":[{"rate":"50-60%","effect":"Hot flashes"},{"rate":"30-40%","effect":"Musculoskeletal pain"},{"rate":"20-30%","effect":"Arthralgia"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1399","moleculeType":"Small molecule","molecularWeight":"293.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting this enzyme, Arimidex reduces estrogen levels in the body, which can help slow or stop the growth of hormone receptor-positive breast cancer cells. This mechanism is particularly effective in postmenopausal women, as their bodies produce less estrogen naturally.","oneSentence":"Arimidex is an aromatase inhibitor that blocks the enzyme responsible for converting androgens to estrogens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:21.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy"},{"name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women following surgery"}]},"trialDetails":[{"nctId":"NCT01602380","phase":"PHASE3","title":"A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-10-17","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":462},{"nctId":"NCT02203331","phase":"PHASE2","title":"Bay98-7196, Dose Finding / POC Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-10-16","conditions":"Endometriosis","enrollment":319},{"nctId":"NCT00327769","phase":"PHASE3","title":"Faslodex Advanced Breast Cancer Local Chinese Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-11","conditions":"Advanced Breast Cancer","enrollment":234}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"arimidex dummy","genericName":"arimidex dummy","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arimidex is an aromatase inhibitor that blocks the enzyme responsible for converting androgens to estrogens. Used for Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women following surgery.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}